Johnson & Johnson (JNJ)
Health Care26 articles
Price chart
Why is JNJ moving?
BearishJul 17Johnson & Johnson (JNJ) reported strong Q2 results but saw a decline in stock price. The company raised its revenue outlook for 2026, indicating expected growth. It is essential to monitor how such earnings announcements impact investor sentiment despite positive projections. This financial performance juxtaposed with stock price behavior highlights market volatility. Understanding these dynamics could help investors make informed decisions.
Read the full story →Johnson & Johnson (JNJ) overview
Johnson & Johnson is a healthcare giant spanning pharmaceuticals and medical devices, known for its deep drug pipeline. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Johnson & Johnson trades on the NYSE under the ticker symbol JNJ. As of the most recent market data, the stock was priced around $253.04, up 1.23% on the session, giving Johnson & Johnson a market capitalization of roughly $609.12B.
Over the past 52 weeks, JNJ has traded between $162.78 and $269.43. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 29.0, a common gauge of how richly the market prices the company's earnings. Johnson & Johnson also pays a dividend, currently yielding around 2.14%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch JNJ
As one of the larger companies in the Health Care sector, Johnson & Johnson is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch JNJ for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Johnson & Johnson's size means its share-price moves can also nudge the index as a whole, making JNJ a stock that even index investors pay attention to.
Market Mood
Latest JNJ news
J&J Stock Falls Despite Strong Q2 Results and Higher 2026 Outlook
Johnson & Johnson (JNJ) reported strong Q2 results but saw a decline in stock price. The company raised its revenue outlook for 2026, indicating expected growth. It is essential to monitor how such earnings announcements impact investor sentiment despite positive projections. This financial performance juxtaposed with stock price behavior highlights market volatility. Understanding these dynamics could help investors make informed decisions.
Read More: J&J Stock Falls Despite Strong Q2 Results and Higher 2026 Outlook
J&J Reports Strong Quarter, Price Target Raised Despite Stock Decline
Johnson & Johnson (JNJ) reported better-than-expected earnings and increased its guidance for the year. However, the stock fell despite this positive news. Analysts have raised their price targets based on the strong performance, indicating confidence in the company's future despite market reactions. The fluctuations highlight the complexities investors navigate in evaluating company performance against stock market responses.
Read More: J&J Reports Strong Quarter, Price Target Raised Despite Stock Decline
3 Stocks to Hold: Focus on AAPL, MSFT, and JNJ
The article identifies three stocks to consider holding through varying market conditions: Apple (AAPL), Microsoft (MSFT), and Johnson & Johnson (JNJ). It emphasizes Apple's strong brand loyalty and innovation, while Microsoft boasts significant growth in cloud services. Johnson & Johnson is noted for its diversified portfolio and stability. By focusing on these companies, investors might mitigate risks and capitalize on reliable growth opportunities during market fluctuations.
Read More: 3 Stocks to Hold: Focus on AAPL, MSFT, and JNJ
Cramer Sees Opportunities: Buy JNJ, PEP, SBUX, STZ, TJX Stocks
Jim Cramer highlighted buying opportunities in five stocks due to a recent market rotation. The June jobs report indicated a slowdown, leading institutions to reposition portfolios. Cramer mentioned PepsiCo (PEP) as a potential bargain ahead of its July 9 earnings report and noted Starbucks (SBUX) as a good buy amidst its turnaround efforts. Additionally, he expressed bullishness on TJX Companies (TJX), given the trend of consumers trading down to off-price retailers. Understanding these dynamics can benefit ordinary investors looking for discounted quality stocks.
Read More: Cramer Sees Opportunities: Buy JNJ, PEP, SBUX, STZ, TJX Stocks
Johnson & Johnson (JNJ) Positioned for Earnings Report
Johnson & Johnson (JNJ) has been identified as the IBD Stock of the Day, indicating strong market interest as it approaches its earnings report. The company is currently in a buy zone, suggesting favorable trading conditions. As the earnings release date approaches, analysts are closely monitoring trading volumes and price movements to gauge investor sentiment. This positioning may lead to increased activity around the upcoming earnings call.
Read More: Johnson & Johnson (JNJ) Positioned for Earnings Report
IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
The iShares U.S. Pharmaceuticals ETF (IHE) has an expense ratio of 0.38% and a dividend yield of 1.62%, while the Invesco Pharmaceuticals ETF (PJP) has a higher expense ratio of 0.57% and a dividend yield of 0.96%. IHE holds 56 positions, heavily concentrated in Eli Lilly (NYSE:LLY) at 24.2% and Johnson & Johnson (NYSE:JNJ) at 20.3%. In contrast, PJP features 29 companies with Eli Lilly at 5.4%. Investors' choice between IHE and PJP hinges on their comfort with company-specific risks within the pharmaceutical sector.
Read More: IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
PEP and JNJ Dividends Required for California's $100,600 Income
To replace California's median household income of $100,600, an investment of approximately $2,874,000 is needed at a 3.5% yield or $1,212,000 at 8.3%. California's living costs are about 10.7% above the national average, pushing investors to consider dividend stocks like PepsiCo (PEP) and Johnson & Johnson (JNJ). PEP offers a current yield of about 4% and raised its quarterly dividend to $1.48, while JNJ's yield is approximately 2% with a quarterly dividend of $1.34. This data highlights the importance of considering dividends for income growth amidst rising costs in California.
Read More: PEP and JNJ Dividends Required for California's $100,600 Income
Portfolio Needs $400K to Replace $40K Income at 10% Yield
To replace $40,000 in lost income, a portfolio needs between $400,000 (10% yield) and $1.14 million (3.5% yield) in dividend-generating assets. A 3.5% dividend-growth portfolio can produce approximately $154,000 annually by year 20. The impact of going part-time may add $8,000 to $15,000 to the income replacement target due to lost employer health coverage and 401(k) matching. Financial professionals vary in their motivations, emphasizing the importance of finding a fiduciary adviser.
Read More: Portfolio Needs $400K to Replace $40K Income at 10% Yield
BMY vs JNJ: Healthcare Revenue Comparison for 2025
In fiscal 2025, Bristol Myers Squibb (BMY) reported revenue of nearly $48.2 billion, a decrease of approximately 0.2% from the previous year, with a net income of roughly $7.1 billion and a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved approximately $94.2 billion in revenue, reflecting an increase of nearly 6% year-over-year, accompanied by a net income of around $26.8 billion and a net margin of 28.5%. BMY's balance sheet showed a debt-to-equity ratio of 2.6 and a current ratio of 1.3, while its free cash flow reached nearly $12.8 billion. These figures underscore the differing financial health and revenue growth trajectories of these two healthcare companies.
Read More: BMY vs JNJ: Healthcare Revenue Comparison for 2025
BMY and JNJ Financials: 2025 Revenue Numbers Declared
For FY 2025, Bristol Myers Squibb (BMY) reported revenue of approximately $48.2 billion, reflecting a slight decline of 0.2% year-over-year, while net income was $7.1 billion, yielding a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved revenue of about $94.2 billion, marking a 6.0% increase, with a net income of nearly $26.8 billion and a net margin of 28.5%. BMY's debt-to-equity ratio stood at 2.6x, while JNJ's was 0.6x, indicating differing financial leverage. Their performance could influence investor strategies given the contrasting growth potential and stability they provide.
Read More: BMY and JNJ Financials: 2025 Revenue Numbers Declared
PFE and JNJ Annual Dividend Income of $3,540 for Investors
Investors holding 500 shares each of Pfizer (PFE) and Johnson & Johnson (JNJ) can expect an annual passive income of $3,540 on a $127,000 investment, with a blended yield of 2.79%. JNJ recently increased its quarterly dividend to $1.34, marking its 64th consecutive increase, supported by a AAA-rated balance sheet and $19.7 billion in free cash flow. Meanwhile, PFE's yield stands at 6.8%, reflecting stock compression. JNJ reported Q1 2026 revenues of $15.426 billion in pharmaceuticals, an 11.2% year-over-year increase, while MedTech revenue reached $8.636 billion, up 7.7%.
Read More: PFE and JNJ Annual Dividend Income of $3,540 for Investors
Johnson & Johnson (JNJ) Shares Up 53% in Past Year
Johnson & Johnson (JNJ) shares have gained 53% over the past year and are up 15% year-to-date. Leerink Partners upgraded JNJ's shares on May 13th, raising the price target from $252 to $265. The firm believes that JNJ's new drugs will contribute to revenue growth and share price performance. Additionally, JNJ has seen a 7.7% increase in share price over the past month amid market liquidity issues.
Read More: Johnson & Johnson (JNJ) Shares Up 53% in Past Year
J&J (JNJ) Expands US Rollout of TECNIS Cataract Lens
Johnson & Johnson (JNJ) has announced the expansion of its TECNIS PureSee cataract lens throughout the United States. This lens technology aims to improve vision for cataract patients and is expected to enhance J&J's offerings in the ophthalmic market. While precise financial figures were not disclosed, the expansion supports J&J’s strategic goals in healthcare innovation. This move could potentially impact market share positively for JNJ in the medical device sector, increasing competition in the ophthalmic field.
Read More: J&J (JNJ) Expands US Rollout of TECNIS Cataract Lens
Dividend Strategy Beats 4% Rule by Up to $430K Over 20 Years
A dividend strategy yielding 3.8% can outperform the 4% withdrawal rule by $430,000 over 20 years on a $1 million portfolio. Initially generating about $38,000 annually, this method does not necessitate selling shares. Underlying factors include a projected 7% annual growth in dividends, potentially reaching $147,000 by year 20. Market dynamics show that while S&P 500 dividends fell only 8% during the 2008-09 crisis, share prices decreased by 57%, indicating the resilience of dividend income.
Read More: Dividend Strategy Beats 4% Rule by Up to $430K Over 20 Years
Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
A $1 million dividend portfolio generates approximately $43,770 annually, subjected to $7,515 in taxes at the 24% bracket. This portfolio includes holdings such as Realty Income (O), Schwab U.S. Dividend Equity ETF (SCHD), and Johnson & Johnson (JNJ). The taxable portion of income is divided into qualified and ordinary income, impacting the total tax liability. The advantage of using a Roth IRA allows the full income to remain untaxed, highlighting the significance of account placement for tax efficiency.
Read More: Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
The iShares U.S. Pharmaceuticals ETF (IHE) has posted a 1-year return of 39.70% as of May 20, 2026, while the iShares Global Healthcare ETF (IXJ) reported a return of 10.00%. Both funds have similar expense ratios, with IHE at 0.38% and IXJ at 0.40%. IHE's assets under management (AUM) stand at $883.6 million, compared to IXJ's $3.6 billion. Additionally, IHE has a higher dividend yield of 1.70% versus IXJ's 1.50%, indicating potential advantages for investors favoring domestic pharmaceutical exposure.
Read More: IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
Dividend Portfolio Yield Impacts After Taxes for California Residents
A retiree in California with a $1 million dividend portfolio earning a 5% yield generates $50,000 in gross income. After federal and state taxes, the net income drops to approximately $38,300, compared to $42,500 in states with no income tax, highlighting a $4,200 annual after-tax gap. California taxes dividends as ordinary income, with state rates ranging from 9.3% to 13.3%. Key dividend stocks mentioned include Johnson & Johnson (JNJ) at a 2.2% yield and Procter & Gamble (PG) at 3.0%.
Read More: Dividend Portfolio Yield Impacts After Taxes for California Residents
Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
Johnson & Johnson (JNJ) reported Q1 2026 revenue of $24.06 billion, representing a 9.9% year-over-year increase, driven by TREMFYA's growth of 68.3% and DARZALEX's increase of 22.5% to $3.96 billion. The company raised its full-year guidance to a midpoint of $100.8 billion. AbbVie (ABBV) also exceeded expectations with Q1 revenue of $15 billion and a year-over-year increase of 12.4%. AbbVie's Skyrizi reached $4.48 billion with a 30.9% increase, offsetting Humira's 38.6% decline.
Read More: Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
Berkshire's Dividend Stock Picks: JNJ, MCD, PG for Market Downturn
Warren Buffett's Berkshire Hathaway held nearly $375 billion in cash at the end of 2025, indicating potential readiness for market downturn investments. The article identifies Johnson & Johnson (JNJ), McDonald's (MCD), and Procter & Gamble (PG) as favorable dividend stock picks in such a scenario. JNJ currently trades at about 19 times forward earnings but could become more attractive with a 20% to 25% pullback, yielding a dividend of 2.5% to nearly 3%. The dividends and consistent earnings growth of these companies highlight their stability during economic uncertainty.
Read More: Berkshire's Dividend Stock Picks: JNJ, MCD, PG for Market Downturn
Johnson & Johnson (JNJ) Launches Shockwave C2 Catheter for Coronary Procedures
Johnson & Johnson (JNJ) announced the launch of the Shockwave C2 Aero coronary catheter designed to treat coronary artery disease. This device aims to improve patient outcomes by facilitating easier and more effective treatments. The introduction of such innovative products could enhance JNJ's market position in the cardiovascular segment. As the demand for advanced medical technologies continues to grow, this launch may positively influence JNJ's market performance.
Read More: Johnson & Johnson (JNJ) Launches Shockwave C2 Catheter for Coronary Procedures
Dividend Portfolio Generates $17,500 Income from $500,000 Investment
A $500,000 portfolio yielding 3.5% can generate $17,500 annually, or about $1,460 per month, surpassing the federal minimum wage of $15,080 before taxes. For a 6% yield, the income increases to $30,000 annually, equating to $2,500 monthly, which also exceeds many state minimum wages. Notable investment options include Schwab U.S. Dividend Equity ETF (SCHD) and Realty Income (O), with established dividend increases. This analysis highlights the importance of yield versus compounding in portfolio growth over time.
Read More: Dividend Portfolio Generates $17,500 Income from $500,000 Investment
Bayer (BAYRY) Loses Bid Against Johnson & Johnson Prostate Drug Claims
A US judge rejected Bayer's (BAYRY) motion to block claims regarding Johnson & Johnson's (JNJ) prostate cancer drug. This ruling may affect Bayer's legal exposure related to similar product liabilities. The case underscores ongoing competitive pressures in the pharmaceutical sector, particularly regarding patent and claim disputes. Bayer's strategy and resource allocation may be impacted by this decision as they navigate the legal landscape.
Read More: Bayer (BAYRY) Loses Bid Against Johnson & Johnson Prostate Drug Claims
Johnson & Johnson (JNJ) Stock Target Increased After Earnings Report
Stifel has raised its price target for Johnson & Johnson (JNJ) following the company's latest earnings report. This upward adjustment reflects positive performance metrics, although specific earnings figures or percentage increases were not detailed. The revised target suggests analysts have confidence in JNJ's growth trajectory and profitability. As a result, the expectation of improved stock performance could influence investor sentiment and trading activity in JNJ shares.
Read More: Johnson & Johnson (JNJ) Stock Target Increased After Earnings Report
Johnson & Johnson (JNJ) Analyst Insights on Potential Price Drops
Limited data available — the article discusses Jim Cramer's perspective on Johnson & Johnson (JNJ), suggesting that if the stock experiences a significant decline, investors should consider buying. However, no specific price targets, trading volumes, or percentage changes are provided. The insights reflect market sentiment but lack concrete data that would impact decision-making or stock evaluation. As such, the article does not offer any verified facts or numbers relevant to JNJ's current financial standing.
Read More: Johnson & Johnson (JNJ) Analyst Insights on Potential Price Drops
J&J (JNJ) Q1 Revenue Surges 10% to $24.1B, Beats Analyst Estimates
Johnson & Johnson (JNJ) reported first-quarter revenue of $24.1 billion, a nearly 10% increase from the previous year, surpassing analyst estimates of $23.6 billion. Adjusted earnings were $2.70 per share, exceeding the consensus estimate of $2.66. Key drug sales included $4 billion for Darzalex and $1.6 billion for Tremfya, both outperforming projections, while Stelara sales fell 60% to $656 million. JNJ raised its full-year revenue forecast to a midpoint of approximately $100.8 billion, slightly above Wall Street's estimate of $100.6 billion.
Read More: J&J (JNJ) Q1 Revenue Surges 10% to $24.1B, Beats Analyst Estimates
S&P 500 Rallies 3.6% Following U.S.-Iran Ceasefire Announcement
The S&P 500 closed up 3.6% week-to-date, driven by a ceasefire announcement between the U.S. and Iran. The Nasdaq Composite and Dow also rallied 4.7% and 3%, respectively, marking their best week since November. President Trump's announcement of a two-week pause on Iranian strikes has alleviated market tensions. However, financial commentator Jim Cramer expressed concerns about market overconfidence and ongoing geopolitical risks, advising caution ahead of upcoming corporate earnings reports, including Goldman Sachs (GS) and Johnson & Johnson (JNJ).
Read More: S&P 500 Rallies 3.6% Following U.S.-Iran Ceasefire AnnouncementMore Health Care stocks
Frequently asked questions
Is Johnson & Johnson in the S&P 500?
Yes. Johnson & Johnson (JNJ) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is JNJ in?
Johnson & Johnson is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest JNJ news?
This page collects recent Johnson & Johnson (JNJ) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Johnson & Johnson's stock price?
As of the most recent market data, Johnson & Johnson (JNJ) traded at approximately $253.04. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Johnson & Johnson's market cap?
Johnson & Johnson has a market capitalization of roughly $609.12B, based on its most recent share price and shares outstanding.
What is JNJ's P/E ratio?
JNJ trades at a trailing price-to-earnings ratio of about 29.0. The P/E ratio compares a company's share price to its earnings per share.